Harkof-LS Junior Syrup is a pediatric formulation combining Ambroxol (15mg/5ml), Levosalbutamol (0.5mg/5ml), and Guaifenesin (50mg/5ml), designed to provide comprehensive relief in respiratory conditions characterized by mucus hypersecretion and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, exerts bronchodilatory effects by relaxing bronchial smooth muscles, which helps alleviate bronchospasm and enhances airflow. Guaifenesin serves as an expectorant, promoting the mobilization and expulsion of mucus, thus aiding in effective cough clearance. This combination is particularly beneficial in managing acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases in children. Harkof-LS Junior Syrup is intended for oral administration, with dosing adjusted according to the patient’s age and clinical condition. It is important to use this medication under medical supervision to monitor therapeutic response and avoid potential side effects such as tachycardia, tremors, or gastrointestinal disturbances. This synergistic formulation offers a multifaceted approach to respiratory symptom management, improving patient comfort and respiratory function.